Table 3 Hazard ratios (HR) for overall survival (OS) and progression-free survival (PFS), cause-specific hazard ratios for cumulative incidence of relapse (CIR) and non-relapse mortality (NRM) and 95% confidence intervals (CI) obtained with multivariable Cox proportional hazards models.
5-year OS | 5-year PFS | 5-year CIR | 5-year NRM | |||||
|---|---|---|---|---|---|---|---|---|
HR (95% CI) | (Overall) p-value | HR (95% CI) | (Overall) p-value | HR (95% CI) | (Overall) p-value | HR (95% CI) | (Overall) p-value | |
TCI index* | ||||||||
Low | 1.00 | 1.00 | 1.00 | 1.00 | ||||
Int/High | 1.12 (0.97–1.30) | 0.13 | 1.00 (0.88–1.14) | 0.95 | 0.74 (0.61–0.91) | 0.004 | 1.24 (1.04–1.48) | 0.02 |
Conditioning intensity* | ||||||||
RIC | 1.00 | 1.00 | 1.00 | 1.00 | ||||
MAC | 1.03 (0.87–1.20) | 0.76 | 1.00 (0.87–1.15) | 0.97 | 0.83 (0.67–1.04) | 0.10 | 1.16 (0.96–1.39) | 0.13 |
Age at allo-HCT (per 10 years older) | 1.35 (1.24–1.48) | <0.0001 | 1.19 (1.10–1.28) | <0.0001 | 0.94 (0.84–1.05) | 0.25 | 1.44 (1.30–1.60) | <0.0001 |
Donor type | (0.002) | (0.03) | (0.75) | (0.0008) | ||||
HLA-matched related | 1.00 | 1.00 | 1.00 | 1.00 | ||||
Unrelated (10/10) | 1.16 (0.99–1.35) | 0.07 | 1.02 (0.88–1.17) | 0.83 | 0.92 (0.75–1.13) | 0.43 | 1.11 (0.92–1.33) | 0.28 |
Unrelated (9/10) | 1.49 (1.20–1.85) | 0.0003 | 1.28 (1.06–1.55) | 0.01 | 0.95 (0.69–1.29) | 0.74 | 1.62 (1.26–2.08) | 0.0001 |
Year of allo-HCT (per year later) | 1.00 (0.97–1.03) | 0.97 | 0.99 (0.97–1.02) | 0.47 | 0.98 (0.94–1.02) | 0.29 | 1.00 (0.97–1.04) | 0.88 |
HCT–CI at allo-HCT | (0.006) | (0.03) | (0.28) | (0.10) | ||||
1.00 | 1.00 | 1.00 | 1.00 | |||||
Intermediate risk | 1.22 (1.02–1.46) | 0.03 | 1.07 (0.91–1.26) | 0.40 | 0.99 (0.77–1.27) | 0.92 | 1.14 (0.93–1.41) | 0.21 |
High risk | 1.33 (1.11–1.58) | 0.001 | 1.25 (1.07–1.46) | 0.005 | 1.20 (0.94–1.53) | 0.14 | 1.29 (1.05–1.58) | 0.02 |
KPS at allo-HCT | ||||||||
90 or 100 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
≤80 | 1.44 (1.25–1.66) | <0.0001 | 1.27 (1.11–1.44) | 0.0003 | 1.19 (0.98–1.46) | 0.08 | 1.35 (1.14–1.60) | 0.0006 |
DIPSS | (0.02) | (0.09) | (0.13) | (0.04) | ||||
Low (0) | 0.65 (0.38–1.11) | 0.12 | 0.76 (0.48–1.18) | 0.22 | 1.10 (0.60–2.02) | 0.76 | 0.53 (0.27–1.05) | 0.07 |
Low-intermediate risk (1–2) | 1.00 | 1.00 | 1.00 | 1.00 | ||||
High-intermediate risk (3–4) | 1.04 (0.87–1.24) | 0.68 | 1.05 (0.90–1.23) | 0.53 | 1.34 (1.05–1.70) | 0.02 | 0.88 (0.71–1.09) | 0.25 |
High risk (5–6) | 1.33 (1.08–1.64) | 0.007 | 1.23 (1.02–1.48) | 0.03 | 1.24 (0.90–1.70) | 0.18 | 1.20 (0.94–1.52) | 0.14 |
CMV status patient/donor | ||||||||
+/– | 1.14 (0.97–1.35) | 0.10 | 1.10 (0.95–1.27) | 0.21 | 0.90 (0.71–1.15) | 0.40 | 1.23 (1.03–1.49) | 0.03 |
Other | 1.00 | 1.00 | 1.00 | 1.00 | ||||
Driver mutation | (0.009) | (0.0006) | (0.01) | (0.05) | ||||
JAK2 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
CALR | 0.79 (0.62–0.99) | 0.04 | 0.74 (0.60–0.91) | 0.004 | 0.64 (0.45–0.90) | 0.01 | 0.82 (0.63–1.07) | 0.14 |
MPL | 0.60 (0.36–1.00) | 0.05 | 0.58 (0.37–0.90) | 0.01 | 0.45 (0.21–0.95) | 0.04 | 0.70 (0.41–1.21) | 0.20 |
Triple-negative | 0.83 (0.55–1.25) | 0.37 | 0.87 (0.61–1.26) | 0.47 | 1.02 (0.61–1.71) | 0.94 | 0.76 (0.45–1.28) | 0.30 |
ATG use | ||||||||
No | 1.00 | 1.00 | 1.00 | 1.00 | ||||
Yes | 0.94 (0.79–1.12) | 0.50 | 1.02 (0.88–1.19) | 0.78 | 1.23 (0.97–1.55) | 0.09 | 0.90 (0.73–1.09) | 0.28 |
